Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy
NCT ID: NCT00911911
Last Updated: 2012-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
66 participants
INTERVENTIONAL
2007-01-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FEC 100 + TAXOTERE
FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE
TAXOTERE 100 mg/m²/cycle
1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100
Blood sampling
Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
BIOPSY
Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
SURGERY
Surgery after neoadjuvant chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
BIOPSY
Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
SURGERY
Surgery after neoadjuvant chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically proven breast carcinoma
* Neo-adjuvant chemotherapy with anthracyclines and/or taxanes
* No prior chemotherapy
* Written informed consent
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Oscar Lambret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BONNETERRE Jacques, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Oscar Lambret
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intercommunal Hospital
Annemasse, , France
Centre Oscar Lambret
Lille, , France
Hopital Saint Vincent
Lille, , France
Centre Henri Becquerel
Rouen, , France
Geroges PIANTA Hospital
Thonon-les-Bains, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPAM 2006-10
Identifier Type: -
Identifier Source: org_study_id
NCT00959673
Identifier Type: -
Identifier Source: nct_alias